BEHANDLUNG VON MIGRÄNE

European patent · EP3955933 · In force

Register entry

Publication number
EP3955933
Application number
EP20722147
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 7, 2020
Published
Feb 23, 2022
Granted
Nov 29, 2023
Protection ends at the latest
Apr 6, 2040
Next annual fee due
Apr 30, 2027
IPC classes
A61K 31/58 (2006.01)
A61P 29/00 (2006.01)
Priority
US 201962833994 P 15.04.2019
PCT application
PCT/US2020/027008 07.04.2020
PCT publication
WO2020/214452 22.10.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 27, 2026

    Change

    Published in Swissreg on 27.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. Oct 9, 2024

    Change

    Published in Swissreg on 09.10.2024

  4. May 1, 2024

    Change

    Published in Swissreg on 01.05.2024

  5. Feb 15, 2024

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 15.02.2024

  6. Nov 29, 2023

    Granted

    Published in Swissreg on 29.11.2023

Parties

Holder

VistaGen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

343 Allerton Avenue, South San Francisco, CA 94080, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

MONTI, Louis

Mountain View, CA 94040, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.